The TPA controversy and the drug approval process. The view of the Cardiovascular and Renal Drugs Advisory Committee

JAMA. 1988 Oct 21;260(15):2250-2.
No abstract available

Publication types

  • Review

MeSH terms

  • Cerebral Hemorrhage / chemically induced
  • Humans
  • Mass Media
  • Myocardial Infarction / drug therapy
  • Professional Staff Committees / organization & administration*
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Streptokinase / therapeutic use
  • Tissue Plasminogen Activator / adverse effects
  • Tissue Plasminogen Activator / therapeutic use*
  • United States
  • United States Food and Drug Administration / organization & administration*

Substances

  • Recombinant Proteins
  • Streptokinase
  • Tissue Plasminogen Activator